TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29622506
Drug: Polypill (aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (aspirin, statin, and two blood pressure lowering drugs)
Study: 22465565
Drug: Sucrose octaacetate
Normalized name: Sucrose Octaacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose octaacetate solution (bitter)
Study: 16261108
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous morphine (SC)
Study: 16261108
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural morphine (ED)
Study: 8826100
Drug: Albendazole 800
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 800 mg with a fatty breakfast for three consecutive days
Study: 25893651
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) for 10 weeks prior to bariatric surgery
Study: 21724838
Drug: NNC126‐0083 (0.01,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC126‐0083 (0.01, 0.02, 0.04, or 0.06 mg protein/kg)
Study: 21724838
Drug: NNC126‐0083 (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC126‐0083 (0.06 mg protein/kg)
Study: 21724838
Drug: NNC126‐0083 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC126‐0083 (all doses)
Study: 11846327
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen plus medroxyprogesterone acetate (CCEP) 0.625 mg plus 5 mg daily
Study: 31609077
Drug: MAS062D lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAS062D lotion
Study: 31585489
Drug: Hydrophilic cream
Normalized name: HYDROPHILIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrophilic cream
Study: 28693622
Drug: Social Recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Recovery Therapy (SRT) plus optimised treatment as usual (enhanced standard care)
Study: 1750102
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg base chloroquine once weekly
Study: 1750102
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg daily proguanil
Study: 1750102
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg base chloroquine/kg (25 CQ) over three days for treatment of breakthroughs
Study: 7102531
Drug: Oral pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pindolol 5 mg
Study: 7102531
Drug: Oral pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pindolol 10 mg
Study: 361333
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol 80 mg
Study: 7102531
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol 0.3 mg/kg
Study: 28727703
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) 7 µ/kg
Study: 23077087
Drug: Memantine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 20 mg/day
Study: 15071189
Drug: Carbenoxolone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (100 mg three times per day)
Study: 11903914
Drug: i.v. erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. erythromycin 2 mg kg‐1 over 20 min
Study: 11903914
Drug: sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual isosorbide 10 mg
Study: 18586645
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - Soybean oil capsules
Study: 6240166
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline (2% alcoholic solution)
Study: 30170579
Drug: BTI320 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTI320 4 g (low dose)
Study: 29071948
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) therapy, treated by EA stimulation of bilateral Neiting (ST 44), Fenglong (ST 40), Zusanli (ST 36), Huaroumen (ST 24), Tianshu (ST 25), Wailing (ST 26), Shuidao (ST 28), Fujie (SP 14), Daheng (SP 13) for 25 min, once every other day, 3 times per week for 3 months.
Study: 29071948
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for weight reduction).
Study: 21868752
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU recombinant human follicle‐stimulating hormone (rFSH) administered on alternate days for 90 days
Study: 21868752
Drug: Nonantioxidant vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonantioxidant vitamin supplements
Study: 21868752
Drug: rFSH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFSH treatment in patients with high basal DFI values (>15%)
Study: 21868752
Drug: Vitamin supplements
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplements in patients with high basal DFI values (>15%)
Study: 17443649
Drug: nab-paclitaxel 70
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 70 mg/m2
Study: 17443649
Drug: nab-paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel 100 mg/m2
Study: 10233320
Drug: Intracutaneous injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous injections of botulinum A toxin (200 mouse units)
Study: 7846789
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (placebo, 11 patients)
Study: 19890266
Drug: d‐amphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine (10 mg)
Study: 27396241
Drug: linagliptin (5mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin (5mg, monotherapy or combination therapy)
Study: 11451319
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ketoconazole daily for 3 months
Study: 718514
Drug: GITS 15/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: GITS 15/125 (15 mg/hr, administered twice a day)
Study: 718514
Drug: Conventional 250‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 250‐mg acetazolamide tablets
Study: 28375887
Drug: Intraoperative soft‐tissue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative soft‐tissue infiltration of bupivacaine liposome injectable suspension
Study: 26500462
Drug: High Protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Protein group (HP) consuming >3 g/kg/d of dietary protein
Study: 17713332
Drug: Ozone treatment
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone treatment for 40 seconds
Study: 17713332
Drug: Air treatment
Normalized name: GLYCERIN 3.88 mg in 1 mL TOPICAL SHAMPOO [HAIR TREATMENT PREMIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air treatment for 40 seconds (Control)
Study: 15107371
Drug: Pethidine (PET)
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine (PET) 50 mg intramuscularly plus placebo intravenously
Study: 15107371
Drug: Placebo (PLC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLC) intramuscular and intravenous
Study: 12269647
Drug: MFNS 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFNS 200 microg, twice daily
Study: 12269647
Drug: MFNS 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFNS 400 microg, twice daily
Study: 9839094
Drug: Acarbose (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (25 mg t.i.d. to 100 mg t.i.d. over 24 weeks)
Study: 2910779
Drug: Intravenous cis-platinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cis-platinum injection
Study: 19247240
Drug: Once-weekly dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly dressing change
Study: 19247240
Drug: Twice-weekly dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly dressing change
Study: 9784909
Drug: Chronic administration
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic administration of propionyl-L-carnitine (1.5 mg/d for 1 month)
Study: 7908532
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg and 100 mg
Study: 7908532
Drug: Pindolol 5
Normalized name: pindolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 5 mg twice daily and 15 mg twice daily
Study: 3198977
Drug: Tiapamil (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (lower dose)
Study: 3198977
Drug: Tiapamil (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (higher dose)
Study: 3198977
Drug: Nifedipine (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (lower dose)
Study: 3198977
Drug: Nifedipine (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (higher dose)
Study: 22655053
Drug: peginterferon-α2a 180
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon-α2a 180 µg once weekly and ribavirin 800 mg daily
Study: 18545197
Drug: L-carnitine L-tartrate
Normalized name: L-carnitine (free form) (as L-carnitine L-tartrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine L-tartrate (LCLT) 2 g/d for 23 days
Study: 12548090
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN, 30 mg TID)
Study: 12548090
Drug: Pentaerythrityl tetranitrate
Normalized name: pentaerythrityl tetraethylhexanoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaerythrityl tetranitrate (PETN, 80 mg TID)
Study: 10526912
Drug: Intensified antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified antihypertensive therapy (IT group)
Study: 10526912
Drug: Routine antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antihypertensive therapy (RT group)
Study: 7574765
Drug: Intra-arterial (IA)
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial (IA) chemotherapy
Study: 29221491
Drug: Gantenerumab 225
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantenerumab 225 mg
Study: 20546699
Drug: Cognitive-Behavioral Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Treatment (CBT) for BZ Discontinuation
Study: 20546699
Drug: Taper plus
Normalized name: DRESSING,RESTORE PLUS TAPERED H#519959
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper plus relaxation
Study: 16308444
Drug: Wobenzym (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wobenzym (1 tablet for 6 kg weight, administered for 3 months)
Study: 10227638
Drug: Oral high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high-dose methylprednisolone
Study: 8457123
Drug: Erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate (0.5 g twice a day for 5 days)
Study: 19714275
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment with sling for comfort
Study: 15008768
Drug: Incremental infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incremental infusion of oxytocin maintained after 5 cm dilation (Group A)
Study: 8711499
Drug: Treatment continuation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment continuation (Epirubicin/Ifosfamide)
Study: 8711499
Drug: Treatment interruption
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment interruption (control)
Study: 30415601
Drug: Sacubitril‐valsartan (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril‐valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily)
Study: 22287674
Drug: Nitrate diet
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate diet (22 g nitrate/kg DM)
Study: 8375267
Drug: Human NPH
Normalized name: INSULIN HUMAN NPH 100 UNIT/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human NPH insulin
Study: 9521197
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with acyclovir and/or ganciclovir
Study: 1870247
Drug: Intensive dietetic-hygienic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive dietetic-hygienic measures and hypolipidemic (mainly clofibrate and/or probucol) and antihypertensive (mainly beta-blockers and/or diuretics) drugs
Study: 27807291
Drug: Extracorporeal Shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shockwave Therapy (ESWT)
Study: 12413620
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 800 microg
Study: 9848486
Drug: HVB bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HVB bisacodyl suppositories
Study: 9848486
Drug: PGB bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGB bisacodyl suppositories
Study: 23135343
Drug: Colobreathe dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colobreathe dry powder for inhalation (CDPI, one capsule containing colistimethate sodium 1,662,500 IU, twice daily)
Study: 23135343
Drug: Tobramycin inhaler
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin inhaler solution (TIS, 300 mg/5 ml, twice daily for three 28-day cycles)
Study: 23135343
Drug: Colobreathe dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colobreathe dry powder for inhalation (CDPI)
Study: 23135343
Drug: Tobramycin inhaler
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin inhaler solution (TIS)
Study: 16480401
Drug: CDP571 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP571 (10 mg/kg, intravenous, 8-weekly through to week 32)
Study: 10855459
Drug: Cyclandelate 800
Normalized name: Cyclandelate
DrugBank: Cyclandelate (DB04838)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate 800 mg bid
Study: 9116778
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (900-1200 mg/day)
Study: 29528704
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (Cholecalciferol) 50,000 IU in tablet form, monthly, for 1 yr
Study: 29528704
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 IU in tablet form, monthly, for 1 yr
Study: 24407182
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg every other day)
Study: 20604918
Drug: A-Part Gel
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-Part Gel
Study: 16116007
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 3 mg
Study: 12183495
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg caffeine 1 h preexercise (Precaf)
Study: 12183495
Drug: 6 x
Normalized name: Mepilex AG 6 x 6"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 x 1 mg/kg caffeine every 20 min throughout steady-state (Durcaf)
Study: 12183495
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 5 ml/kg Coca-Cola during steady-state and TT (Coke)
Study: 28228425
Drug: Prebiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic supplementation (8 g oligofructose-enriched inulin/d)
Study: 29041979
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) treatment
Study: 24166792
Drug: Other one-carbon
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other one-carbon metabolism biomarkers
Study: 22060248
Drug: Unguided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unguided self-help (10-week web-based treatment without therapist support)
Study: 19082528
Drug: Monotherapy (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (calcium supplement)
Study: 18251131
Drug: Terlipressin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (1 mg every four hours for 48 hours)
Study: 18251131
Drug: Albumin (8g/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (8g/L of removed ascites)
Study: 14679443
Drug: Ampicillin-sulbactam/amoxicillin-clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam/amoxicillin-clavulanate
Study: 14679443
Drug: Linezolid and
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid and comparators (oral and intravenous formulations)
Study: 2692971
Drug: Fenticonazole (2%)
Normalized name: fenticonazole
DrugBank: Fenticonazole (DB13434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenticonazole (2%) spray
Study: 20561625
Drug: 45 g
Normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g whey protein isolate
Study: 20561625
Drug: 45 g
Normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g sodium caseinate
Study: 15830219
Drug: 0.65 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.65 g/kg alcohol
Study: 15571441
Drug: 0.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 g/kg (placebo)
Study: 15332386
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate (SFC) combination (50/500 microg)
Study: 11164668
Drug: Topical silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silver sulfadiazine combined with cerium nitrate (SSD‐CN)
Study: 24121806
Drug: Topical silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silver sulfadiazine (SSD)
Study: 8492964
Drug: Droxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxicam (20 mg/day, orally administered)
Study: 30143316
Drug: Ultrasound-guided femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided femoral nerve block with up to 20mL of 0.3mL.kg‐1 of 0.5% bupivacaine and intravenous tramadol
Study: 30143316
Drug: Standard management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard management group; up to 3mL of 0.9% saline in the femoral sheath and intravenous tramadol
Study: 20593142
Drug: Magnesium (Mg)
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (Mg) supplementation during CABG surgery
Study: 20593142
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Mg supplementation)
Study: 20593142
Drug: NAC untreated
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAC untreated group (placebo with dextrose solution)
Study: 18703812
Drug: Warfarin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (in SPORTIF V)
Study: 18703812
Drug: Warfarin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (in SPORTIF III)
Study: 6734709
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no oral contraceptive steroids)
Study: 26910661
Drug: Nonanimal stabilized
Normalized name: nonanal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonanimal stabilized hyaluronic acid injection
Study: 22135154
Drug: Preoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotics (cefazolin 1 g given <30 minutes prior to skin incision)
Study: 22135154
Drug: Intraoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative antibiotics (cefazolin 1 g at cord clamping)
Study: 22135154
Drug: Preoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotics or intraoperative antibiotics
Study: 20194915
Drug: Pregabalin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (600 mg/d after titration over 8 weeks)
Study: 18538052
Drug: High urinary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High urinary flow rate (10 mL kg(‐1) h(‐1))
Study: 18538052
Drug: Low urinary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low urinary flow rate (3 mL kg(‐1) h(‐1))
Study: 10857818
Drug: Heparin-surface-modified (HSM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-surface-modified (HSM) intraocular lenses
Study: 8853141
Drug: Low-dose systemic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose systemic administration of heparin (2,500 units)
Study: 47280
Drug: Indoprofen 200
Normalized name: Neoprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indoprofen 200 mg
Study: 6384073
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (ASA) 500 mg
Study: 6384073
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (ASA) 1500 mg
Study: 30993748
Drug: Simtuzumab (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simtuzumab (combined treatment groups from two phase 2b trials)
Study: 23281759
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg biotin/kg
Study: 23281759
Drug: 0.09 mg
Normalized name: camphor 0.09 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09 mg biotin/kg
Study: 23281759
Drug: 0.12 mg
Normalized name: iodine 0.12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 mg biotin/kg
Study: 23281759
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg biotin/kg